The pharmaceutical industry plays a crucial role in global healthcare, with India being one of the largest contributors. As the third-largest producer of medicines globally, India’s pharmaceutical industry is valued at $50 billion and exports to over 200 countries. The sector benefits from strong government support, including Production Linked Incentive (PLI) schemes, and is expanding rapidly.
Below, we analyze five key pharmaceutical stocks with strong fundamentals and growth potential.
- Marksans Pharma
Marksans Pharma is a global pharmaceutical company specializing in the formulation and manufacturing of pharmaceutical products. It primarily focuses on over-the-counter (OTC) and prescription drugs in pain management, cardiovascular, and gastrointestinal treatments.
| Metric | Value |
| Market Cap | ₹10,411 crore |
| Current Price | ₹230.35 |
| Revenue Mix | 74% OTC, 26% Prescription Drugs |
| Key Therapy Areas | Pain Management (44%), Cough & Cold (14%), Cardiovascular (4%) |
| P/E Ratio | 30.5 (Sector P/E: 45.79) |
| Debt-to-Equity Ratio | < 1 |
| Return on Equity (ROE) | 16.5% |
Marksans Pharma has strong partnerships with global retailers like Walmart and Tesco and has four R&D centers with over 70 products in its pipeline.
- Caplin Point Laboratories
Caplin Point Laboratories is involved in manufacturing active pharmaceutical ingredients (APIs), finished formulations, and research & development.
| Metric | Value |
| Market Cap | ₹14,400 crore |
| Current Price | ₹1,894 |
| Revenue from Latin America | 83% |
| Key Market Focus | US, Canada, Australia, Russia, China, Latin America |
| P/E Ratio | 29.31 (Sector P/E: 45.79) |
| Debt-to-Equity Ratio | < 1 |
| Return on Equity (ROE) | 24.2% |
Caplin Point has 55+ new drug applications in progress and runs a healthcare e-commerce platform with 1,500+ customers.
- Eris Life Sciences
Eris Life Sciences specializes in branded pharmaceutical products, targeting chronic and acute therapies.
| Metric | Value |
| Market Cap | ₹15,777 crore |
| Current Price | ₹1,159 |
| Revenue Mix | 90% Domestic, 10% Export |
| Key Therapy Areas | Anti-diabetes (32%), Cardiac Care (16%), Vitamins & Nutrients (14%), Dermatology (13%) |
| P/E Ratio | 45.4 (Sector P/E: 36.3) |
| Debt-to-Equity Ratio | < 1 |
| Return on Equity (ROE) | 16.3% |
Eris Life Sciences has been expanding through acquisitions and recently entered the export injectable business.
- Shilpa Medicare
Shilpa Medicare focuses on APIs, contract research, and manufacturing services with a strong presence in oncology, biosimilars, and drug delivery systems.
| Metric | Value |
| Market Cap | ₹6,854 crore |
| Current Price | ₹701 |
| Revenue Mix | APIs (68%), Formulations (29%), Others (3%) |
| Geographical Revenue Split | India (43%), USA (17%), Europe (28%), Others (12%) |
| P/E Ratio | 138.4 (Sector P/E: 36.3) |
| Debt-to-Equity Ratio | < 1 |
| Return on Equity (ROE) | 1.71% |